Related Experiment Videos
Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina
Katharina Heck1, Katja Hatz1,2, Marco Cattaneo3,4
1Medical Retina & Clinical Research Department, Vista Augenklinik, Binningen, Switzerland.
Introduction:
Faricimab has been shown to be effective for treatment of macular edema (ME) due to retinal vein occlusion (RVO). So far, there is only limited evidence in real-life settings and hard-to-treat cases.
Methods:
This multicenter, retrospective study evaluated patients with branch or central (including hemi-central) RVO treated with a faricimab treat-and-extend regimen with at least 6 months of follow-up (FU). Data included best-corrected visual acuity (BCVA), center-point retinal thickness (CRT), central subfield thickness (CST), presence of intra- and subretinal fluid in the 1, 3, and 6 mm Early Treatment Diabetic Retinopathy Study (ETDRS) grid zones, number of injections, and adverse events at baseline and at 1, 3-4, and 6 months of faricimab therapy. Pretreated eyes were additionally evaluated at predefined time points of the pretreatment period.
Results:
A total of 112 eyes from 111 patients, including 13 treatment-naive and 99 pretreated eyes, were included. BCVA improved in treatment-naïve eyes from 0.46 ± 0.28 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.32 ± 0.28 logMAR 6 months later (p = 0.041). BCVA remained stable in pretreated eyes (0.20 ± 0.25 vs. 0.21 ± 0.29 logMAR; p = 0.7). CRT and CST improved in both groups: in treatment-naïve eyes, CRT from 522 to 267 µm (p < 0.001) and CST from 467 to 301 µm (p = 0.032); in pretreated eyes, CRT from 275 to 253 µm (p = 0.009) and CST from 315 to 293 µm (p = 0.001). Significant resolution in retinal fluid was shown in the central 1 mm (p ≤ 0.014), 3 mm (p ≤ 0.013), and 6 mm zones (p ≤ 0.013) of the ETDRS grid in both groups. Over 6 months, treatment-naïve and pretreated eyes received a mean of 5 ± 1 injections. One systemic adverse event and no intraocular inflammation were recorded during FU.
Conclusion:
This study demonstrates good real-world efficacy with significant drying and promising safety profile of faricimab in eyes with ME due to RVO, including a high proportion of hard-to-treat cases, over a 6-month period.
